The authors discuss the role of epithelial‐mesenchymal transition of breast cancer stem cells (BCSCs) in the setting of trastuzumab resistance and approaches of reducing or eradicating BCSCs in HER2‐positive breast cancer.
[Stem Cells]
6807162
{6807162:R3KP64G7}
apa
50
1
161181
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-0dc048f7fd2cc8f83050b2488f0a5440%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22R3KP64G7%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Qiu%20et%20al.%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EQiu%2C%20Y.%2C%20Yang%2C%20L.%2C%20Liu%2C%20H.%2C%20%26amp%3B%20Luo%2C%20X.%20%28n.d.%29.%20Cancer%20Stem%20Cell-Targeted%20Therapeutic%20Approaches%20for%20Overcoming%20Trastuzumab%20Resistance%20in%20HER2-Positive%20Breast%20Cancer.%20%3Ci%3ESTEM%20CELLS%3C%5C%2Fi%3E%2C%20%3Ci%3En%5C%2Fa%3C%5C%2Fi%3E%28n%5C%2Fa%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fstem.3381%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fstem.3381%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3DR3KP64G7%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20Stem%20Cell-Targeted%20Therapeutic%20Approaches%20for%20Overcoming%20Trastuzumab%20Resistance%20in%20HER2-Positive%20Breast%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%22%2C%22lastName%22%3A%22Qiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Libo%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Honghong%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaobo%22%2C%22lastName%22%3A%22Luo%22%7D%5D%2C%22abstractNote%22%3A%22Application%20of%20the%20anti-HER2%20drug%20trastuzumab%20has%20significantly%20improved%20the%20prognosis%20of%20patients%20with%20the%20HER2-positive%20subtype%20of%20breast%20cancer.%20However%2C%2050%25%20of%20patients%20with%20HER2%20amplification%20relapse%20due%20to%20trastuzumab%20resistance.%20Accumulating%20evidence%20indicates%20that%20breast%20cancer%20is%20driven%20by%20a%20small%20subset%20of%20cancer-initiating%20cells%20or%20breast%20cancer%20stem%20cells%20%28BCSCs%29%2C%20which%20have%20the%20capacity%20to%20self-renew%20and%20differentiate%20to%20regenerate%20the%20tumor%20cell%20hierarchy.%20Increasing%20data%20suggest%20that%20BCSCs%20are%20resistant%20to%20conventional%20therapy%2C%20including%20chemotherapy%2C%20radiotherapy%2C%20and%20endocrine%20therapy%2C%20which%20drives%20distant%20metastasis%20and%20breast%20cancer%20relapse.%20In%20recent%20years%2C%20the%20trastuzumab%20resistance%20of%20breast%20cancer%20has%20been%20closely%20related%20to%20the%20prevalence%20of%20BCSCs.%20Here%2C%20our%20primary%20focus%20is%20to%20discuss%20the%20role%20of%20epithelial-mesenchymal%20transition%20%28EMT%29%20of%20BCSCs%20in%20the%20setting%20of%20trastuzumab%20resistance%20and%20approaches%20of%20reducing%20or%20eradicating%20BCSCs%20in%20HER2-positive%20breast%20cancer.%20%5Cu00a9%20AlphaMed%20Press%202021%20Significance%20Statement%20In%20HER2-positive%20breast%20tumors%2C%20trastuzumab%20target%20therapy%20has%20shown%20efficacy%20in%20removing%20non-BCSCs%20while%20failed%20to%20eradicate%20partial%20BCSCs.%20Targeting%20BCSCs%20might%20be%20a%20promising%20approach%20to%20prevent%20distant%20metastasis%20and%20local%20recurrence%20of%20HER2-positive%20breast%20cancer.%20Herein%2C%20we%20aim%20to%20discuss%20the%20mechanism%20of%20trastuzumab%20resistance%20in%20BCSCs%20of%20HER2-positive%20cancer%20cells%20and%20the%20approaches%20of%20reducing%20or%20eradicating%20BCSCs%2C%20especially%20after%20anti-HER2%20therapy.%22%2C%22date%22%3A%22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fstem.3381%22%2C%22ISSN%22%3A%221549-4918%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fstemcellsjournals.onlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fstem.3381%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-14T20%3A45%3A52Z%22%7D%7D%5D%7D
Qiu, Y., Yang, L., Liu, H., & Luo, X. (n.d.). Cancer Stem Cell-Targeted Therapeutic Approaches for Overcoming Trastuzumab Resistance in HER2-Positive Breast Cancer. STEM CELLS, n/a(n/a). https://doi.org/https://doi.org/10.1002/stem.3381 Cite
